- 英文名称6-Bromo-[1,2,4]Triazolo[1,5-A]Pyridine
- 中文名称6-溴-[1,2,4]三唑并[1,5-a]吡啶
- IUPAC名称6-bromo-[1,2,4]triazolo[1,5-a]pyridine
- 其它别名4]三唑并[1; 6-Bromo-[1,2,4]Triazolo[1,5-A]Pyridine
- CAS编号356560-80-0
- MFCD编号:MFCD08689534
- EINECS号:801-547-5
- 分子式:C6H4BrN3分子量:198.02
- 产品CID: 1364880
- 产品分类有机原料→分子砌块→芳杂环类化合物→吡啶类化合物
相似化合物
868362-18-9 1310680-10-4 1401624-81-4欧盟法规
ECHA物质C&L通报上下游产品
CAS号138888-98-9 N'-(5-溴吡啶-2-基)-... | CAS号1075260-65-9 N-(5-bromo-2-py... | CAS号1072-97-5 2-氨基-5-溴吡啶 | CAS号1160790-18-0 9-氮杂吲哚-5-硼酸频哪醇酯 | CAS号943845-23-6 [1,2,4]三唑并[1,5-...📜N-(5-Bromo-2-Pyridinyl)Imidoformamide置于吡啶,Hydroxylamine-O-Sulfonic Acid体系中,用 甲醇 作为反应溶剂,化学反应生成 6-溴-[1,2,4]三唑并[1,5-A]吡啶
参考文献:Wo2008/128953
标题:Wo2008/128953
专利信息
专利号:US-2012077802-A1
优先权日:2009-06-10
标题 :Histamine h3 inverse agonists and antagonists and methods of use thereof
发明人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN
权利人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are spiro-cyclic compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein.
专利号:US-8404670-B2
优先权日:2009-02-11
标题:Histamine H3 inverse agonists and antagonists and methods of use thereof
发明人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SPEAR KERRY L
权利人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SPEAR KERRY L; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.